IMV Inc. 2020 Biotech Europe Forum Investor Presentation

IMV Inc. presented its DPX immunotherapy platform at the 20th Annual Biotech in Europe Forum in September 2020. The presentation highlighted the company's first-in-class drug delivery platform with clinical activity in cancer and infectious diseases, alongside development of a DPX-based COVID-19 vaccine candidate. IMV showcased positive phase 2 data in oncology and partnerships with leading organizations including Merck and the Wistar Institute.